Rockwell Medical (RMTI) Stock Price, News & Analysis

Company Overview

Rockwell Medical, Inc. is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients. TRIFERIC is delivered via dialysate and is intended to replace iron losses that occur during the dialysis process, helping to maintain hemoglobin levels without the need for intravenous iron supplements. In addition to TRIFERIC, Rockwell Medical offers a generic injectable formulation of calcitriol, a form of vitamin D used to manage secondary hyperparathyroidism in CKD patients.

Since its founding in 1991, Rockwell Medical has conducted research, clinical development, and regulatory activities primarily in the United States. The company collaborates with specialty distributors and dialysis providers to commercialize its products and is exploring further innovations, including oral formulations of its iron therapy. Rockwell Medical’s operations are led by an experienced management team with backgrounds in nephrology, pharmaceutical development, and health-care commercialization, reflecting its commitment to improving patient outcomes in the CKD community.

Key Stats

• Today's Range: $1.18 to $1.23
• 50-Day Range: $0.93 to $1.83
• 52-Week Range: $0.78 to $5.15
• Volume: 267,753 shs
• Average Volume: 647,068 shs
• Market Capitalization: $41.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Moderate Buy

Rockwell Medical Stock Analysis - MarketRank™

Rockwell Medical scored higher than 63% of companies evaluated by MarketBeat, and ranked 362nd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Rockwell Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Rockwell Medical has a consensus price target of $4.00, representing about 227.6% upside from its current price of $1.22.

Amount of Analyst Coverage

Rockwell Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Rockwell Medical are expected to decrease in the coming year, from $0.03 to ($0.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rockwell Medical is -20.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rockwell Medical is -20.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rockwell Medical has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.36% of the float of Rockwell Medical has been sold short.

Short Interest Ratio / Days to Cover

Rockwell Medical has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rockwell Medical has recently increased by 51.96%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rockwell Medical does not currently pay a dividend.

Dividend Growth

Rockwell Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -2.35

Percentage of Shares Shorted

5.36% of the float of Rockwell Medical has been sold short.

Short Interest Ratio / Days to Cover

Rockwell Medical has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rockwell Medical has recently increased by 51.96%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Rockwell Medical this week, compared to 2 articles on an average week.

Search Interest

Only 6 people have searched for RMTI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

3 people have added Rockwell Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Rockwell Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,413.00 in company stock.

Percentage Held by Insiders

Only 3.60% of the stock of Rockwell Medical is held by insiders.

Percentage Held by Institutions

Only 23.31% of the stock of Rockwell Medical is held by institutions.

RMTI Stock Analysis - Frequently Asked Questions

How have RMTI shares performed this year?

Rockwell Medical's stock was trading at $2.04 at the beginning of 2025. Since then, RMTI stock has decreased by 40.1% and is now trading at $1.2210.

How were Rockwell Medical's earnings last quarter?

Rockwell Medical, Inc. (NASDAQ:RMTI) released its earnings results on Thursday, August, 14th. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). The company earned $16.07 million during the quarter, compared to analyst estimates of $16.33 million. Rockwell Medical had a negative trailing twelve-month return on equity of 6.79% and a negative net margin of 2.38%.
Read the conference call transcript.

When did Rockwell Medical's stock split?

Shares of Rockwell Medical reverse split on Friday, May 13th 2022.The 1-11 reverse split was announced on Friday, May 13th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

How do I buy shares of Rockwell Medical?

Shares of RMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rockwell Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rockwell Medical investors own include NVIDIA (NVDA), Super Micro Computer (SMCI), Axcelis Technologies (ACLS), Opera (OPRA), ADMA Biologics (ADMA), ASML (ASML) and InterDigital (IDCC).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/09/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:RMTI
• CIK: 1041024
• Web: www.rockwellmed.com
• Phone: (248) 432-1362
• Fax: 248-960-9119
• Employees: 300
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Rockwell Medical: $4.00
• High Price Target: $5.00
• Low Price Target: $3.00
• Potential Upside/Downside: +229.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 40.50
• P/E Growth: N/A
• Net Income: -$480 thousand
• Net Margins: -2.38%
• Pretax Margin: -2.39%
• Return on Equity: -6.79%
• Return on Assets: -3.77%

Debt

• Debt-to-Equity Ratio: 0.30
• Current Ratio: 2.89
• Quick Ratio: 2.51

Sales & Book Value

• Annual Sales: $87.97 million
• Price / Sales: 0.48
• Cash Flow: $0.13 per share
• Price / Cash Flow: 9.41
• Book Value: $1.01 per share
• Price / Book: 1.20

Miscellaneous

• Outstanding Shares: 34,430,000
• Free Float: 33,191,000
• Market Cap: $41.83 million
• Optionable: Optionable
• Beta: 1.73